TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18511049
Drug: Tegaserod with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod with whole-dose PEG-E
Study: 18511049
Drug: Tegaserod with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod with split-dose PEG-E
Study: 18511049
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with whole-dose PEG-E
Study: 18511049
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with split-dose PEG-E
Study: 18511049
Drug: Whole-dose PEG-E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-dose PEG-E
Study: 18511049
Drug: Split-dose PEG-E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose PEG-E
Study: 8872728
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nitrendipine (Bypress; Bayer) 2 hours before SWL
Study: 6385259
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 every 3 weeks)
Study: 6385259
Drug: Mitoxantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (12 mg/m2 every 3 weeks)
Study: 6385259
Drug: Doxorubicin or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin or Mitoxantrone (as secondary therapy)
Study: 22709418
Drug: Balanced saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced saline solution (group 2)
Study: 17686111
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray 110 microg
Study: 2642329
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg) daily, taken twice daily
Study: 135666
Drug: Adriamycin alone
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin alone (60 mg/m2 intravenously every 3 weeks)
Study: 135666
Drug: Adriamycin plus
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin plus streptozotocin (adriamycin 60 mg/m2 every 3 weeks + streptozotocin 500 mg/m2/day intravenously for 5 days every 3 weeks)
Study: 31586368
Drug: Internet-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based self-help program SaveMySkin (12-week program based on cognitive-behavioral therapy)
Study: 22568471
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of DHA supplementation
Study: 22012833
Drug: Dobutamine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (2.5 μg/kg/min) administered postoperatively for 2 days
Study: 2018732
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid creams (four types representative of potency groups)
Study: 6605681
Drug: Fenbufen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen (1,000 mg a day)
Study: 6605681
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg a day)
Study: 6605681
Drug: Naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (750 mg a day)
Study: 9821992
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol
Study: 24575769
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group with sterile saline solution
Study: 22971499
Drug: Target effect‐site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target effect‐site remifentanil concentration of 1 ng/ml (R1 group)
Study: 22971499
Drug: Target effect‐site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target effect‐site remifentanil concentration of 2 ng/ml (R2 group)
Study: 19491611
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire regarding awareness of HPV
Study: 11351147
Drug: Intraduodenal artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal artificial bile infusion (80 mol% bile acids; 15 mol% phospholipids; 5 mol% cholesterol)
Study: 11351147
Drug: Intraduodenal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal saline infusion (placebo)
Study: 11351147
Drug: Intraduodenal artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal artificial bile infusion
Study: 9734735
Drug: Intraduodenal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal saline infusion
Study: 9859958
Drug: Vaccine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (various rgp vaccines)
Study: 2684920
Drug: Relaxation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation and music therapy (combined)
Study: 23838870
Drug: 2-L polyethylene
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L polyethylene glycol electrolyte solution enriched in vitamin C
Study: 23838870
Drug: 4-L polyethylene
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-L polyethylene glycol electrolyte solution
Study: 21966835
Drug: American Diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: American Diabetes Association 75 g curve
Study: 21966835
Drug: American Diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: American Diabetes Association 100 g curve
Study: 21966835
Drug: World Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: World Health Organization 75 g curve
Study: 15579530
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 2 g/kg monthly for 4 months
Study: 7699642
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) and Placebo
Study: 8489059
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil 10 micrograms with 0.2 mg epinephrine
Study: 31562147
Drug: Taste solution
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taste solution test
Study: 25451430
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.5 mg/kg)
Study: 23385548
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with piritramid intravenously by infusion pump
Study: 23385548
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain management with oral non-steroidal analgesics
Study: 20850348
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion beginning at 25 μg/kg/min and morphine boluses (P)
Study: 20850348
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion beginning at 2 μg/kg/h and midazolam boluses (F)
Study: 20850348
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and fentanyl infusions beginning at 25 μg/kg/min and 0.5 μg/kg/h (PF)
Study: 22015327
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) alone (ethinyl estradiol [EE] 0.035 mg + norethindrone [NET] 1 mg)
Study: 11876511
Drug: bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (400 mg once daily)
Study: 12123487
Drug: gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (600 mg twice daily)
Study: 11876511
Drug: fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate (200 mg once daily)
Study: 7813537
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg, 0.4 g/kg body weight per day for 5 consecutive days, followed by the same dose once every 2 weeks for 3 months)
Study: 25207898
Drug: Sodium cantharidinate/vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cantharidinate/vitamin B6 + GP regimen (30 ml cantharidinate/vitamin B6 for four 21-day cycles)
Study: 15285036
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of regular insulin (20 U) followed by glucose infusion (500 mL 50 g/L dextrose)
Study: 15285036
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of regular insulin (20 U)
Study: 9597405
Drug: Dalteparin (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (a low molecular weight heparin)
Study: 8270968
Drug: Chemotherapy maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy maintenance regimens (continuous vs cyclic)
Study: 2643934
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (flexible-dose treatment for averaging ten weeks)
Study: 25542267
Drug: Onartuzumab with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onartuzumab with weekly paclitaxel
Study: 20861645
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (topical application of a steroid ointment)
Study: 18502235
Drug: Chickpeas (728
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chickpeas (728 g/week for 12 weeks)
Study: 10511348
Drug: Transdermal E2-norethindrone
Normalized name: estradiol / norethindrone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2-norethindrone acetate (50-140 microg/day)
Study: 10511348
Drug: Transdermal E2-norethindrone
Normalized name: estradiol / norethindrone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2-norethindrone acetate (50-250 microg/day)
Study: 10511348
Drug: Transdermal E2-norethindrone
Normalized name: estradiol / norethindrone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2-norethindrone acetate (50-400 microg/day)
Study: 10511348
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 (50 microg/day)
Study: 10511348
Drug: Transdermal E2-norethindrone
Normalized name: estradiol / norethindrone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2-norethindrone acetate
Study: 7747857
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.2 mg.kg‐1
Study: 7747857
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam 0.3 mg.kg‐1
Study: 31425577
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel treatment for 6 weeks
Study: 31425577
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel treatment for 6 weeks
Study: 28558718
Drug: Lactic-fermented egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactic-fermented egg white (LE) with 8 g of protein daily for 8 weeks
Study: 28558718
Drug: Lactic-fermented egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactic-fermented egg white (LE) with 4 g of protein daily for 8 weeks
Study: 24243316
Drug: Tigecycline 50
Normalized name: tigecycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline 50 mg q12h
Study: 22445776
Drug: GSK598809 (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 (dopamine D3 receptor antagonist)
Study: 9822993
Drug: Oral psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral psychotropic medications with clubhouse program attendance
Study: 8107739
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (15 mg/kg, max 1000 mg)
Study: 2779692
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (2 mg)
Study: 2779692
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (3 mg)
Study: 2779692
Drug: Prednisolone sodium
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone sodium phosphate (30 mg)
Study: 31397077
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (single dose prior to surgery)
Study: 31397077
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (no preoperative and postoperative antibiotics)
Study: 26070226
Drug: Hysteroscopic-guided pertubal
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic-guided pertubal diluted bupivacaine infusion (0.25%)
Study: 24605899
Drug: Metformin 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,500 mg daily
Study: 22622912
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural injections with local anesthetic and steroids
Study: 22622912
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic with or without steroids
Study: 7917149
Drug: Verapamil (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (180 to 480 mg/day)
Study: 1199816
Drug: L-dopa administered
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa administered as a solution
Study: 1199816
Drug: L-dopa administered
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa administered in tablet form
Study: 1199816
Drug: L-dopa administered
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa administered at short intervals
Study: 22196471
Drug: Nasal Cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Cannula (NC; 0.5 L/kg/min)
Study: 22196471
Drug: Nasal Prongs
Normalized name: SET,INFUSION,5-PRONG BAXTER #L5C4446
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Prongs with Continuous Positive Airway Pressure (NP-CPAP; 5-10 L/min, pressure 5 cmH(2)O)
Study: 22196471
Drug: Nasopharyngeal Catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasopharyngeal Catheter (NPC; 0.3-0.5 L/kg/min)
Study: 19193738
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no immunosuppressive treatment)
Study: 15195855
Drug: Rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole sodium (20 mg single dose)
Study: 15195855
Drug: Standard reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reference preparation
Study: 8598260
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg orally every 8 hours)
Study: 2758767
Drug: 250HD3 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250HD3 (35 mcg/day for 25 days/month)
Study: 337983
Drug: Nefopam 15
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 15 mg
Study: 30543350
Drug: Immediate cytoreductive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate cytoreductive nephrectomy (CN) followed by sunitinib therapy
Study: 30543350
Drug: Deferred CN
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred CN after 3 cycles of sunitinib therapy
Study: 23384799
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy (EBRT) followed by high dose rate (HDR) brachytherapy of 2 × 8.5 Gy
Study: 18985628
Drug: Flurazepam 30
Normalized name: flurazepam 30 mg oral capsule
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurazepam 30 mg (positive control)
Study: 15319390
Drug: CD56(dim)CD16(+)CD69(+) NK
Normalized name: DIM-SA
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD56(dim)CD16(+)CD69(+) NK cells count >1.0 x 10(6)/l
Study: 15319390
Drug: CD56(dim)CD16(+)CD69(+) NK
Normalized name: DIM-SA
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD56(dim)CD16(+)CD69(+) NK cells count <1.0 x 10(6)/l
Study: 11417983
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (radiotherapy, tamoxifen)
Study: 8485272
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg and 60 mg
Study: 26548879
Drug: 3 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 daily denture brushings using water at ambient temperature
Study: 26548879
Drug: 3 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 daily denture brushings using water at ambient temperature plus coconut soap
Study: 26548879
Drug: 3 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 daily denture brushings using water at ambient temperature plus dentifrice
Study: 26548879
Drug: 3 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 daily denture brushings using water at ambient temperature combined with immersion in sodium perborate solution for 5 minutes before nocturnal sleep
Study: 7476052
Drug: 50 mg.d-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg.d-1 iron supplement, low iron diet
Study: 7476052
Drug: Meat supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat supplement to achieve 15 mg.d-1 iron intake
Study: 1417014
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg tablet administered orally once at 2 hrs prior to cisplatin administration.
Study: 1417014
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose tablet) administered orally once at 2 hrs prior to cisplatin administration.
Study: 1417014
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication with ondansetron injection if satisfactory anti-emetic effects were not obtained.
Study: 1417014
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication with ondansetron injection.
Study: 1417014
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects observed after rescue medication with ondansetron injection.
Study: 30410934
Drug: 0.20% Chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20% Chlorhexidine gel (Plak ®Gel; Polifarma Wellness Srl, Rome, Italy)
Study: 30410934
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (Placebo, Polifarma Wellness Srl, Rome, Italy)
Study: 27082008
Drug: Cognitive-behavioral intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral intervention designed to improve medication adherence and pain-related outcomes
Study: 27082008
Drug: Associations between
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Associations between patient‐ and provider‐reported AMTB and urine drug screening results
Study: 26282661
Drug: Continuous Therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous Therapy (CT)
Study: 26282661
Drug: Fixed Duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Duration Therapy (FDT)
Study: 21160317
Drug: Stapled transanal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stapled transanal rectal resection with a new, curved multifire stapler (TRANSTAR group)
Study: 21160317
Drug: Stapled transanal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stapled transanal rectal resection with 2 traditional circular staplers (STARR group)
Study: 10753980
Drug: rtPA (alteplase)
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rtPA (alteplase) 0.9 mg/kg IV over 1 hour
Study: 2162437
Drug: Cyclic alternating
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic alternating chemotherapy (CT) of COMP and VAN (etoposide, adriamycin, nimustine)
Study: 2162437
Drug: CAV-PVP hybrid
Normalized name: PVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV-PVP hybrid chemotherapy (CTX, ADM, VCR on day 1; cisplatin on day 8; VP-16 on days 8 and 9)
Study: 396651
Drug: Pirenzepine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (25 mg three times per day for 1 week followed by 25 mg two times per day for 3 weeks)
Study: 21299475
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 mg orally, 4 times daily for 14 days
Study: 18564334
Drug: Carvedilol (6.25-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (6.25-25 mg twice daily)
Study: 18564334
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate (50-200 mg twice daily)
Study: 16820580
Drug: GIK (40%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (40% dextrose, K+ 100 mmol.L(‐1), insulin 70 u.L(‐1)) administered at 0.75 mL.kg(‐1) h(‐1) from start of operation until 6 hours after removal of aortic cross-clamp (AXC)